Facioscapulohumeral Muscular Dystrophy Clinical Trial
Official title:
Effects of Antioxidants Supplementation on Muscular Function of Patients Affected by Facioscapulohumeral Dystrophy (FSHD)
On the basis of published data and the investigators' results indicating that oxidative stress may contribute to the peripheral skeletal muscle dysfunction in patients with FSHD, the investigators propose a study to test whether or not an antioxidant supplementation has a therapeutic interest for patients with FSHD. Their results have important implications for the successful implementation of rational antioxidant therapy in FSHD in which cell loss could be linked to oxidative stress.
This study will compare the effect of the therapeutic interest of an antioxidant supplementation on the functional deficits and the molecular muscle abnormalities into two groups of patients affected by FSHD, one treated with the antioxidant supplementation during 17 weeks. The antioxidant by capsule consisted of:Vitamin E (400 mg /day), Selenium (200 µg/day in the form of selenomethionine), Vitamin C (500 mg/day), Zinc (25 mg/day in the form of gluconate). The second one treated with a placebo during 17 weeks. Patients will be assigned to intervention groups by chance, and neither physician, nor patient, will know which product is administrated (study in "double blind"). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00082108 -
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
|
||
Completed |
NCT02579239 -
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
|
Phase 1/Phase 2 | |
Terminated |
NCT02927080 -
Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)
|
Phase 2 | |
Completed |
NCT02625662 -
Facioscapulohumeral Dystrophy in Children
|
||
Recruiting |
NCT04001582 -
The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry
|
||
Recruiting |
NCT06425445 -
Quantitative Assessment of Orofacial Muscle Function in FSHD
|
N/A | |
Terminated |
NCT03943290 -
Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
|
Phase 2 | |
Active, not recruiting |
NCT03458832 -
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
|
||
Completed |
NCT02766985 -
Rasch-analysis of Clinical Severity in FSHD
|
||
Active, not recruiting |
NCT01671865 -
Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy
|
||
Completed |
NCT02413190 -
Bone Health in Facioscapulohumeral Muscular Dystrophy
|
||
Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
Completed |
NCT01437345 -
A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD
|
N/A | |
Completed |
NCT02836418 -
Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06086548 -
Unraveling Metabolic Involvement in Facioscapulohumeral Dystrophy Through Metabolomics
|
||
Completed |
NCT00821548 -
Electrostimulation of Shoulder Girdle and Quadriceps Muscles in Facioscapulohumeral Muscular Dystrophy Patients
|
N/A | |
Completed |
NCT05178706 -
Effectiveness of Upper Extremity Rehabilitation in pwFSHD (Patient With Facioscapulohumeral Dystrophia)
|
||
Completed |
NCT00104078 -
Study Evaluating MYO-029 in Adult Muscular Dystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05019625 -
Biomarker Development for Muscular Dystrophies
|
||
Completed |
NCT03123913 -
Study of Testosterone and rHGH in FSHD
|
Phase 1 |